Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizoribine versus mycophenolate mofetil after living-related kidney transplantation
ChiCTR2300074265Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mizoribine and mycophenolate mofetil in kidney transplant (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of acute rejection. Started Jan 2023; status: recruiting.
02
Drugs
mizoribinemycophenolate mofetil
03
Conditions
kidney transplant
Beyond the preview
Go deeper on ChiCTR2300074265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074265.